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Francisella tularensis is a CDC Category A biological agent and a potential bioterrorist threat. 
There is no licensed vaccine against tularemia in the United States. A long-standing issue with 
potential Francisella vaccines is strain phase variation to a gray form that lacks protective capability 
in animal models. Comparisons of the parental strain (LVS) and a gray variant (LVSG) have 
identified lipopolysaccharide (LPS) alterations as a primary change. The LPS of the F . tularensis 
variant strain gains reactivity to F . novicida anti-LPS antibodies, suggesting structural alterations 
to the O-antigen. However, biochemical and structural analysis of the F . tularensis LVSG and LVS 
LPS demonstrated that LVSG has less O-antigen but no major O-antigen structural alterations. 
Additionally, LVSG possesses structural differences in both the core and lipid A regions, the 
latter being decreased galactosamine modification. Recent work has identified two genes 
important in adding galactosamine (flmF2 and flmK) to the lipid A. Quantitative real-time PCR 
showed reduced transcripts of both of these genes in the gray variant when compared to LVS. 
Loss of flmF2 or flmK caused less frequent phase conversion but did not alter intramacrophage 
survival or colony morphology. The LVSG strain demonstrated an intramacrophage survival 
defect in human and rat but not mouse macrophages. Consistent with this result, the LVSG 
variant demonstrated little change in LD50 in the mouse model of infection. Furthermore, the 
LVSG strain lacks the protective capacity of F . tularensis LVS against virulent Type A challenge. 
These data suggest that the LPS of the F . tularensis LVSG phase variant is dramatically altered. 
Understanding the mechanism of blue to gray phase variation may lead to a way to inhibit this 
variation, thus making future F . tularensis vaccines more stable and efficacious.
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but can still effectively cause diseases in humans. F. tularensis sub-
species novicida (F. novicida) and F. tularensis subspecies mediasi-
atica are other known subspecies of Francisella that are considered 
relatively avirulent for immunocompetent humans but are capable 
of causing systemic infection in other mammals (Ellis et al., 2002; 
Keim et al., 2007).
There are no approved vaccines available to prevent or treat 
tularemia in the United States (Oyston, 2009). An attenuated live 
vaccine strain, F. tularensis LVS (Ft LVS), was derived from a Type 
B isolate of the pathogen (Oyston, 2009) and is used as a vac-
cine in Europe and is in clinical trials for potential approval in 
the US. It elicits diverse protection in humans, monkeys, guinea 
pigs, and mice depending on the route of vaccination against sys-
temic challenge with virulent Type A F. tularensis (Eigelsbach and 
Downs, 1961). The molecular basis for the attenuation of Ft LVS still 
remains unknown, though candidate factors have been identified 
(Rohmer et al., 2006). Eigelsbach (Eigelsbach et al., 1951; Eigelsbach 
IntroductIon
Francisella tularensis is a gram-negative, facultative intracellular 
pathogen that causes tularemia in humans and animals (Oyston 
et al., 2004; Keim et al., 2007; Sjostedt, 2007). The host can be 
infected by several routes including the lungs (inhalational), skin, 
or mucous membranes (cutaneous) or by ingestion of contami-
nated food or water (gastrointestinal) (Keim et al., 2007; Sjostedt, 
2007). F. tularensis has been characterized as a category A bio-de-
fense organism by the Centers for Disease Control and Prevention 
because of its high lethality and infectivity, particularly by the aero-
sol route. There are two major human virulent subspecies of F. 
tularensis: F. tularensis subspecies tularensis (Type A strain) found 
in North America and F. tularensis subspecies holarctica (Type B 
strain) found in Europe, Asia as well as North America (Ellis et al., 
2002). The Type A strain is highly infectious and when inhaled, 
even low doses (<10 bacteria) can cause life-threatening disease in 
humans (Sjostedt, 2007). Type B strains are considered less virulent 
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(University of New Mexico, Albuquerque, NM, USA). For most 
experiments, bacteria were grown overnight (∼24 h) on Choc II 
agar (BD Biosciences, San Jose, CA, USA) at 37°C as the frequency 
of phase variation was minimal in these conditions. Liquid cul-
tures were grown overnight (∼16 h) in tryptic soy broth (TSB; 
Difco Laboratories, Detroit, MI, USA) containing 0.1% cysteine 
HCl (Sigma-Aldrich, St. Louis, MO, USA) for specified times as 
described in the results or Figure legends.
GenetIc manIpulatIon
Constructs for the deletion of FTL1611 (flmF2) and FTL1609 (flmK) 
were made in pJC84 (Wehrly et al., 2009). The ∼1 kb upstream 
region of flmF2 was amplified using forward primer JG1823 (5′-a
aacgagctcgGGGTTATGGTGACTTCTGCATC-3′) with SacI restric-
tion site at the 5′ end and reverse primer JG1824 (5′-cgcggatccC
ACAAATACAAAATATATTAACCTTAATTAATGCTATTATAACC-
3′) with a 5′ BamHI restriction site. The ∼1 kb downstream region 
was amplified using forward primer JG1825 (5′-cgcggatccAATAT
TGTTTTAAGCTAATGAAT  CAATACTTATTAAATTCTTAG-3′) 
and reverse primer JG1826 (5′-acgcgtcgacGTATTATATTTTTAG
TAGCAGCTGTTGCTGTTAT-3′) with BamHI and SalI 5′ flank-
ing  restriction  sites,  respectively.  Similarly,  the  flmK  upstream 
region was amplified by JG2290 (5′-aaacgagctcgGATCTAATAC 
TGGATACCACTCATTATC-3′)  forward  primer  with  a  5′  SacI 
site  and  JG2291  (5′-cgcggatccCTTCTTTACCCTCAAATAGA
AACTTATAC-3′) reverse primer with a 5′ BamHI site, and the 
downstream  region  using  the  JG2292  (5′-cgcggatccGATTTAT
CAGCATTAATTACTTTGATAAGCTAAG-3′)  forward  primer 
with  a  5′  BamHI  site  and  JG2293  (5′-acgcgtcgacCATAGATAA 
GCGTACAGTTGTTTCATG-3′) reverse primer with a 5′ SalI site. 
Fragments were cloned in pJC84 sequentially and the construct 
was transformed into Ft LVS followed by chromosomal recom-
bination using the procedure described by Wehrly et al. (2009). 
Mutants were confirmed by PCR amplification and sequencing of 
the deleted region.
mIcroscopy
Choc II plates containing bacteria were visualized under oblique 
light settings as suggested by Robert Miller at Dynport Vaccine 
Company LLC, Frederick, MD, USA and as described by Eigelsbach 
(Eigelsbach et al., 1951). Briefly, a focused light source, concave 
mirror and dissecting microscope with 10× objective magnifica-
tion and a transparent stage were used to visualize blue and gray 
variants. The concave mirror was placed horizontally tilted upward 
so that the light beam would hit the upper concave region and 
the distance between mirror and the microscope is adjusted so 
that the light beam would reflect on the plate sitting on the stage 
of the microscope. Blue and gray colonies were observed and 
counted using these conditions. Samples were prepared for elec-
tron microscopy from overnight (∼16 h) grown cultures of Ft LVS 
or Ft LVSG in TSB containing 0.1% cysteine HCl using methods 
as described previously (Mohapatra et al., 2008). In brief, cells 
were pelleted by centrifugation, washed in PBS, and fixed with 
2.5% warm glutaraldehyde for 15 min. followed by fixing with a 
combination of 2.5% glutaraldehyde and 1% osmium tetroxide 
in 0.1 M sodium cacodylate (pH 7.3) for 15 min at 4°C. Staining 
of the cells was accomplished by using 0.25% uranyl acetate in 
and Downs, 1961) first reported colony variants of the prototypical 
virulent Type A SchuS4 strain and Ft LVS, which were identified on 
the basis of colony morphology (rough colonies and smooth colo-
nies) and their appearance under a field microscope viewed with 
oblique light, where Ft LVS/SchuS4 appears blue and the variant 
as gray. Gray variants were reported to be less virulent with a lethal 
dose of >107 colony forming units (CFU) and were less immuno-
genic/protective in challenge studies, where they afforded mini-
mal protection to Type A challenge (Eigelsbach et al., 1951). These 
variants also differentially reacted to acriflavine agglutination, and 
demonstrated variable stability of colony morphology upon sub-
culturing (Eigelsbach et al., 1951). The observation of gray variants 
depended on growth conditions including culture media, size of 
inoculum, pH, and duration of culture growth. Hartley et al. (2006) 
also identified the spontaneous gray variants of three F. tularensis 
strains (LVS, SchuS4, and HN63), further suggesting that blue to 
gray variation is a frequent and perhaps common occurrence in 
wildtype strains in the environment.
Gray variants were first examined at the molecular level by 
Cowley et al. (1996). This variant (LVSG; Ft LVSG) demonstrated 
differential survival in certain macrophage types and the lipopoly-
saccharide (LPS) of this variant, which possessed a LPS O-antigen, 
was found to possess altered anti-LPS monoclonal antibody reac-
tivity and stimulated increased nitric oxide (NO) production in 
macrophages. A rough gray variant (lacking an LPS O-antigen) was 
also recently characterized (Hartley et al., 2006). This variant was 
identified on the basis of size and opacity, grew slower, had reduced 
intramacrophage survival, and poorly protected against Type A F. 
tularensis challenge. These studies suggested that LPS played an 
important role in this phase variation phenomenon.
In the present study, we confirmed and extended the pheno-
typic characterization of the gray variants and further analyzed the 
LPS of one of these strains. Multiple LPS alterations were noted, 
including those in O-antigen, core and lipid A. The gray variant 
primarily characterized in this study, Ft LVSG, possessed a full 
length O-antigen (as opposed to previously characterized rough 
gray variants), survived less well in human and rat but not mouse 
macrophages and poorly protected against F. tularensis SchuS4 chal-
lenge in the mouse model. It is hoped that a greater understanding 
of the mechanism(s) behind phase variation will lead to phase 
locked strains that no longer vary, thus allowing the construction 
of safer, more immunogenic tularemia vaccines.
materIals and methods
straIns and medIa
Francisella  tularensis  subsp.  holarctica  LVS  (ATCC  29684)  was 
obtained from Karen Elkins (Center for Biologics Research and 
Evaluation, U.S. Food and Drug Administration, Bethesda, MD, 
USA). F. novicida (U112) was obtained from ATCC, LVSG (a spon-
taneous gray phase variant) was provided by F. Nano (University 
of Victoria, Victoria, BC, Canada). Ft LVSGD (another spontane-
ous gray variant we found to lack O-antigen) was obtained from 
lot  number  703-0102-080  produced  at  Cambrex  BioSciences 
in  Baltimore,  MD,  USA.  The  cell  bank  was  produced  from  a 
lyophilized vial of Ft LVS lot NDBR-101, lot 4 (Salk produced). 
F. tularensis subsp. tularensis strain SchuS4, a Centers for Disease 
Control and Prevention clinical isolate, was provided by Rick Lyons www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  3
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Ft LVS and Ft LVSG carbohydrates were examined and Fraction 1 
contained the O-polysaccharide (OPS), Fraction 2 contained slightly 
lower molecular weight OPS, and Fraction 3 contained the core oli-
gosaccharides (OSs) with some possibly low molecular weight OPS 
repeat units. Fractions 1 and 3 were analyzed by NMR spectroscopy. 
Fraction 1 from both LVS and LVSG were compared to each other 
using 2D NMR. OSs found in Fraction 3 from LVS and LVSG were 
analyzed by 1D proton NMR spectroscopy.
lIpId a analysIs
LPS purification and lipid A isolation
Lipopolysaccharide was isolated using the rapid small-scale isola-
tion method for mass spectrometry analysis as described (Yi and 
Hackett, 2000). Briefly, 1.0 ml of Tri-Reagent (Molecular Research 
Center, Cincinnati, OH, USA) was added to a cell culture pellet 
(2–5 ml of an overnight culture), re-suspended, and incubated at 
room temperature for 15 min. Chloroform (200 μl) was added, 
vortexed, and incubated at room temperature for 15 min. Samples 
were centrifuged for 10 min at 12,000 rpm and the aqueous layer 
was removed. An aliquot of water (500 μl) was added to the lower 
layer and vortexed well. After 15–30 min, the sample was spun down 
and the aqueous layers were combined. The process was repeated 
two more times. The combined aqueous layers were lyophilized 
overnight. Lipid A was isolated after hydrolysis in 1% SDS at 
pH 4.5 (Caroff et al., 1988). Briefly, 500 μl of 1% SDS in 10 mM 
Na-acetate, pH 4.5 was added to a lyophilized sample. Samples 
were incubated at 100°C for 1 h and lyophilized. The dried pellets 
were resuspended in 100 μl of water and 1 ml of acidified ethanol 
(100 μl 4 N hydrochloric acid in 20 ml 95% ethanol). Samples were 
centrifuged at 5,000 rpm for 5 min. The lipid A pellet was further 
washed three times in 1 ml of 95% ethanol. The entire series of 
washes was repeated thrice. Finally, samples were re-suspended in 
500 μl of water, frozen on dry ice, and lyophilized. Alternatively for 
harsher lipid A cleavage conditions, LPS samples were dissolved in 
water, and mixed with the same volume of 10% acetic acid to give 
final 5% acetic acid concentration. Samples were hydrolyzed with 
5% acetic acid (100°C, 2 h, with constant stirring- the precipitate 
appeared after 1 h). The precipitate was collected by centrifugation 
at 14,000 rpm for 6 min, then re-suspended in water and lyophi-
lized. The supernatant was stored for future chemical analyses.
MALDI-TOF mass spectrometry
MALDI-TOF  mass  spectrometry  analysis  of  lipid  A  was  per-
formed on a Voyager spectrometer. The samples were dissolved 
in CH3Cl–CH3OH mixture (3:1) and 1 μl of each mixed with 1 μl 
of 0.5 M 2,5 dihydroxybenzoic acid in methanol matrix solution. 
Other MALDI-TOF experiments were performed using a Bruker 
Autoflex II MALDI-TOF mass spectrometer (Bruker Daltonics, 
Inc., Billerica, MA, USA). Each spectrum was an average of 200 
shots. Calibration was performed with ES Tuning Mix (Agi-lent, 
Palo Alto, CA, USA). Spectra were recorded in both the negative-
ion and positive-ion modes.
GC–MS fatty acid analysis
Fatty acids were analyzed as methyl esters. The lipid-containing 
fraction was dissolved in 0.5 ml of 2 M MeOH–HCl and the mix-
ture was kept at 80°C for 18 h. After cooling down, the hydrolyzate 
0.1 M sodium acetate buffer (pH 6.3) for 45 min, and viewed after 
further processing by transmission electron microscopy using an 
FEI Technai G2 Spirit microscope at 60 kV. Multiple fields (>50) 
were examined to determine the average size (diameter and length) 
and shape of bacteria.
sIlver staInInG and Western BlottInG
Overnight (∼24 h) grown bacteria from Choc II agar plates were 
suspended in PBS at a concentration of 3 × 1010 CFU/ml as deter-
mined previously by the optical density (OD600) of diluted cultures 
and subsequent colony counts on solid agar. Bacteria equalized by 
optical density (OD600) were then pelleted, frozen, and lyophilized 
overnight to obtain ∼20 mg of dry cells. LPS was purified using hot 
phenol/water method using the standard protocol as described by 
Apicella et al. (1994).
Lipopolysaccharide was separated by 15% SDS-PAGE and silver 
stained as described (Clay et al., 2008). Briefly, after fixing overnight 
in 40% ethanol and 5% acetic acid, gels were incubated in 0.7% 
periodic acid in fixing solution for 7 min and subsequently washed 
with multiple exchanges of water. The staining solution (0.013% 
concentrated ammonium hydroxide, 0.02 N sodium hydroxide, 
and 0.67% silver nitrate (w/v) was applied with vigorous agitation 
for 10 min, followed by three washes (each 10 min) in water. Gels 
were developed using a solution containing 0.275% monohydrous 
citric acid (w/v) and 0.0025% formaldehyde. Upon completion, 5% 
acetic acid was used to stop the development.
Purified LPS samples (10 μg/well) were electrophoresed on a 
15% SDS-PAGE gel and transferred on nitrocellulose membrane 
using the Bio-Rad semi-dry transfer system. Immunoblotting was 
performed using either anti-F. tularensis LVS or F. novicida poly-
clonal sera (from infected mice) or monoclonal sera specific to the 
LPS of Ft LVS or F. novicida. Polyclonal sera to Ft LVS or F. novicida 
(1:1000 dilution), commercial F. tularensis FB-11 (1:1000, Abcam, 
Cambridge, MA, USA), F. tularensis LPS specific monoclonal (1:10), 
or F. novicida LPS specific monoclonal (1:10) were used as primary 
antibodies with alkaline phosphatase conjugated goat anti-mouse 
IgG (1:4000) as the secondary antibody. The F. tularensis-specific and 
F. novicida-specific anti-LPS monoclonal antibodies were obtained 
from monoclonal hybridoma cell lines (ImmunoPrecise, Victoria, 
BC, Canada). Blots were developed using 5-bromo-4-chloro-3-
indolyl phosphate/NBT (Sigma-Aldrich) as the substrate.
o-antIGen and core analysIs
Lipopolysaccharide was isolated using the hot phenol/water method 
(Apicella et al., 1994). Crude LPS was enzymatically treated to remove 
contaminating nucleic acids and proteins and ultracentrifuged for 
18 h. The LPS pellet was collected and the carbohydrate portion of 
LPS was released from lipid A via 2 h mild hydrolysis with 1% acetic 
acid at 100°C followed by centrifugation of the lipid A at 3500×g. The 
carbohydrate fraction in the supernatant was extracted threefold 
with chloroform to remove any contaminating lipid A, lyophilized, 
re-suspended in water, filtered through nylon filter 0.2 μm prior 
the HPLC separation, and lyophilized again. Carbohydrates from 
Ft LVS and Ft LVSG of were resolved on a Superdex Peptide HPLC 
column with ammonium acetate used as an eluent. The eluting frac-
tions were pooled and salts removed by repeated evaporations from 
de-ionized water on a rotary evaporator. The elution profiles for the Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 129  |  4
Soni et al.  Francisella blue–gray phase variation
H− reverse   transcriptase (Invitrogen, Carlsbad, CA, USA). cDNA 
was then normalized according to the concentration and 2 ng of 
the converted cDNA was used for quantitative PCR with the SYBR 
green PCR master mixture in the Bio-Rad iCycler apparatus (Bio-
Rad, Hercules, CA, USA). All primers were designed to give 200- to 
220-nucleotide amplicons with melting temperatures of 48–52°C. 
Relative copy numbers and expression ratios of selected genes were 
normalized to the expression of the housekeeping gene (dnaK) and 
calculated as described by Mohapatra et al. (2007).
IntramacrophaGe survIval assays
Human monocyte-derived macrophages (MDMs) were isolated 
using standard procedure as described elsewhere (Mohapatra et al., 
2010) and obtained with informed consent from healthy donors by 
an OSU IRB approved protocol. Intramacrophage survival assays in 
human MDMs were performed using following procedure; 2 × 106 
PBMCs/well (MDMs plus lymphocytes) were plated in a 24-well 
plate resulting in 2 × 105 MDMs/monolayer after adherence of 
MDMs and washing. Francisella spp. were opsonized with 0.1% 
serum for 30 min at 37°C. Macrophages were infected with Ft LVS, 
Ft LVSG and F. novicida at an MOI of 50 and incubated at 37°C 
in a CO2 (5%) incubator for 2 h. Cells were washed and 50 μg/ml 
gentamicin was added to each well and incubated for 30 min. Cells 
were washed and replenished with fresh media containing 10 μg/
ml gentamicin. At various time points cells were washed and lysed 
with 0.1% SDS and plated on Choc II plates to enumerate the 
colony forming units.
mIce vIrulence assays
Bacteria grown overnight (∼24 h) on Choc II plates were scraped 
and suspended, washed twice and diluted in PBS. Four- to six-
week-old BALB/c mice were anesthetized and infected with ∼1000 
bacteria in a 20-μl volume by the intranasal route and dilutions were 
plated on Choc II plates to enumerate the inoculum. Mice were 
anesthetized and challenged with 1000 CFU of overnight (∼24 h) 
grown F. tularensis subsp. tularensis SchuS4 intranasally 4 weeks 
post vaccination and observed daily for survival. These procedures 
were performed as described in an OSU IACUC approved protocol 
in an inspected and approved biosafety level 3 laboratory.
results
Blue–Gray phenotypIc varIatIon
Francisella tularensis LVS phase has been observed to vary from a 
blue (wild-type) colony to a gray colony variant (Eigelsbach et al., 
1951; Cowley et al., 1996). Such gray variants have been both char-
acterized with an extended LPS O-antigen (Cowley et al., 1996) 
as well as a truncated O-antigen (Hartley et al., 2006). Our work 
described here is with the Ft LVSG isolate (a variant with an extended 
O-antigen), but at times comparisons are made to Ft LVSGD (a vari-
ant with no O-antigen). We examined various media conditions and 
growth phases to determine the conditions that affected the degree 
of phase variation. We found that Ft LVSG grows slower than Ft 
LVS, forms smaller colonies on agar surfaces, and appeared gray by 
eye on Choc II agar plates under oblique lighting (Figures 1A,B). 
The frequency of blue to gray phase variation was higher (27–31%) 
in liquid cultures (TSB + 0.1% cysteine HCL) grown to stationary 
phase (typically 30–48 h) and plated on solid agar. The frequency of 
was mixed with 0.5 ml 50% NaCl solution and extracted with 1 ml 
of chloroform. The organic layer was collected and aqueous layer 
extracted two times more with chloroform. Combined organic lay-
ers were extracted again three times with water. Water traces were 
removed from collected chloroform phase by addition of anhydrous 
Na2SO4. The organic phase was then filtered through cotton filters 
prewashed with chloroform, concentrated under the stream of 
nitrogen and applied to GC–MS analyses.
Dephosphorylation of lipid A
To remove phosphate groups from lipid A, samples were treated 
with HF for 48 h at 4°C with constant stirring. HF was evaporated 
from samples under vacuum in a desiccator attached to NaOH trap 
for 1 h then removed with nitrogen.
Trimethylsilyl analysis of fatty acid methyl esters
To show the presence of hydroxyl groups in fatty acids of lipid A, the 
fatty acid methyl esters were treated with TriSil reagent for 30 min at 
80°C. The samples were cooled and dried under a nitrogen stream. 
Derivatized samples were suspended in hexane and filtered through 
cotton filters. Filtrates were condensed under a nitrogen stream 
and analyzed by GC–MS.
Galactosamine quantification
Standards and samples were prepared using the established protocol 
(Kalhorn et al., 2009). Stock solutions of carbohydrate and internal 
standards were prepared in deionized water to a final concentra-
tion of 100 ng/ml. Serial dilution of carbohydrate standards were 
prepared to 0.125–25 ng/ml. Internal standards were prepared to 
a final concentration of 5 ng/ml. Individual samples containing a 
cocktail of carbohydrate standards ranging from 0.125 to 25 ng/
ml in addition to the 5 ng/ml internal standard were prepared and 
lyophilized in glass screw top vials. After lyophilization, 100 ml 
water was added followed by 100 ml 2 M TFA. The standard sam-
ples were sealed with polytetrafluoroethylene (PTFE)-lined caps, 
vortexed briefly and heated at 90°C for 30 min for analysis, flash 
frozen and lyophilized. TFA-treated samples were reconstituted in 
50 μl 0.2 M borate buffer, pH 8.8, and 50 μl 1.0 mg/ml derivatizing/
labeling reagent (AccQ-Tag) in dry acetonitrile. The samples were 
vortexed and incubated at room temperature for 15–30 min after 
which they were dried under nitrogen stream at room tempera-
ture. Derivatized samples were reconstituted in 100 μl of distilled 
water, vortexed, and transferred to injection vials for analysis by 
GC–MS.
For analysis of lipid A samples, 10 mg of lipid A isolated from 
individual preparations was used. The vial was incubated at 90°C 
for 24 h for analysis of galactosamine. Aliquots were then frozen and 
lyophilized to dryness. They were then derivatized by the same pro-
cedure as the standards as described above (Kalhorn et al., 2009).
real-tIme pcr
RNA from log phase (0.4–0.5 optical density at 600 nm) cul-
tures of Ft LVS and Ft LVSG was extracted using the RNeasy kit 
(Qiagen, Valencia, CA, USA). The quality and quantity of RNA 
was determined using the Experion automated electrophoresis 
system (Bio-Rad, Hercules, CA, USA). One microgram of total 
RNA was reverse transcribed to cDNA using Superscript II RNase www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  5
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Glycosyl composition analysis of the OSs released from the 
purified LPS preparations show that the Ft LVS and Ft LVSG OSs 
contain the same glycosyl residues, but there is a large quantitative 
difference, in that the Ft LVS OS contains much larger amounts of 
QuiN and Gal than what is found in the OS from the Ft LVSG strain 
(Table 1). The QuiN could be due to QuiNFo as NMR analysis 
(data not shown) shows a significant resonance at around 8 ppm, 
which is consistent with a formyl proton. During the preparation 
of trimethylsilyl (TMS) methyl glycoside, which is accompanied 
by N-acetylation, this formyl group would have been replaced by 
an acetyl group. The large difference in these components between 
the LPS of Ft LVS and Ft LVSG would indicate that the Ft  LVS 
LPS contains much more of the QuiN/Gal-containing O-antigen 
chain polysaccharide than Ft LVSG. Thus, these data suggest that 
the Ft LVSG LPS has an O-antigen but the O-antigen contains 
fewer repeating units than seen in Ft LVS LPS or that LVSG lipid 
A-core is capped less frequently with O-antigen. Interestingly, even 
though the two variants (Ft LVSG and Ft LVSGD) have distinct 
LPS regarding the amount of O-antigen present (albeit both with 
amounts less than that of wildtype), they give rise to morphologi-
cally similar gray variants.
monoclonal and polyclonal antIBody reactIvIty and lps 
structural analysIs suGGests Blue/Gray straIn lps core 
alteratIons
Western blot analysis was performed on LPS samples using commer-
cially available anti-F. tularensis FB-11 (Figure 2B) antibodies stated 
to be specific to the O-antigen, as well as anti-F. tularensis (Figure 2C) 
phase variation was minimal (2–5%) for bacteria grown on plates 
1–2 days and in log phase liquid cultures. We also observed that the 
frequency of blue to gray phase variation dramatically increased 
when Ft LVS was passed through macrophages (23–27%) or recov-
ered from organs of infected animals (31–36%). We also observed 
that the frequency of forward phase variation in broth grown bac-
teria (blue to gray) was always higher (∼30%) than frequency of 
reverse (gray to blue) phase variation (5–7%).
To  more  clearly  compare  Ft  LVS  to  Ft  LVSG  bacteria,  log 
phase cultures were examined by scanning electron microscopy. 
Comparisons of average cell size were not significantly different, 
but more membrane vesicles were observed in Ft LVSG cultures 
(Figure 1C). It is not clear what impact this increased vesiculation 
has on the subsequent phenotypes described for Ft LVSG.
FT lvsG lps possesses less o-antIGen
It was shown previously that the LPS of Ft LVS and Ft LVSG had dif-
ferential reactivity to monoclonal antibodies stated to be O-antigen 
specific (Cowley et al., 1996), suggesting an O-antigen antigenic 
switch. To further examine the LPS O-antigen and its antigenic 
properties, we purified LPS from Ft LVS, Ft LVSG, F. novicida, Ft 
LVSGD, F. tularensis SchuS4 and a F. tularensis SchuS4 small colony 
gray variant and performed silver staining on SDS-PAGE sepa-
rated samples. Consistent with previously published results, the 
gray variant (Ft LVSG) possessed an O-antigen but Ft LVSGD was 
rough (lacked O-antigen) (Figure 2A). The F. tularensis SchuS4 
small colony gray variant also appeared to produce an LPS with a 
repeating O-antigen.
Figure 1 | Ft LVS blue–gray colony and bacterial morphology. (A) Mixed 
cultures of Ft LVS and phase variant (Ft LVSG) viewed on the surface of a Choc II 
agar plate. Note that Ft LVSG forms smaller colonies that Ft LVS. (B) Blue (LVS) 
and Gray (LVSG) colonies viewed under a compound light microscope by oblique 
lighting. The smaller colonies appeared gray. (C) Transmission electron 
microscopy of Ft LVS and Ft LVSG. While the bacterial dimensions were similar 
between these two strains from measuring >50 fields, the Ft LVSG strain 
formed a large amount of membrane vesicles.Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 129  |  6
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and while the laddering was not observed on Ft LVS LPS Western 
blots with the F. novicida specific antibodies, reactivity was observed 
to a low molecular weight species that is typically lipid A plus core 
(Figures 2B–D). F. novicida LPS did not react at all to the anti-F. 
tularensis LPS or FB-11 antibody, but strongly to a low molecular 
weight species (plus typical laddering) with the F. novicida specific 
monoclonal antibody. Ft LVSG reacted with both F. tularensis and the 
F. novicida anti-LPS monoclonal antibodies. These results are consist-
ent with those of Cowley et al. (1996) with regard to O-antigen ladder 
reactivity, but the lipid A core region is not clearly visible on their gels. 
As expected, LVSGD did not demonstrate the typical O-antigen lad-
der due to its the lack of O-antigen (Figures 2B–D). The F. tularensis 
SchuS4 gray variant reacted with both anti-F. tularensis monoclonal 
antibodies and clearly possesses an O-antigen based on the observed 
laddering. However, the modal chain length or capping frequency of 
this O-antigen, like that of Ft LVSG, appears reduced versus F. tula-
rensis SchuS4 (Figures 2B–D).
Figure 2 | Lipopolysaccharide analysis by Silver staining and Western 
blotting. (A) Silver stained gel of LPS purified from various strains listed above the 
lanes. (B) Immunoblotting of purified LPS of Francisella spp. with the anti-LPS 
O-antigen F . tularensis FB-11 antibody. F . tularensis FB-11 (1:1000) and secondary 
goat anti-mouse IgG (1:4000) were used. (C) Immunoblotting of purified LPS of 
Francisella spp. with F . tularensis anti-LPS specific monoclonal antibodies. F . 
tularensis IgG (1:10) and secondary goat anti-mouse IgG (1:4000) were used. 
(D) Immunoblotting of purified LPS of Francisella spp. with F . novicida anti-LPS 
specific monoclonal antibodies. F . novicida #5 IgG (1:10) and secondary goat 
anti-mouse IgG (1:4000) were used. (e) Immunoblotting of LPS with polyclonal 
sera specific to Ft LVS or to F . novicida. Polyclonal sera (1:1000) and secondary 
goat anti-mouse IgG (1:4000) were used. Lane assignments; M (Molecular weight 
marker), LVS (blue colonies), LVSG (gray variant), Fn (F . novicida), LVSGD (rough 
gray variant), Ft4 (F . tularensis SchuS4), Ft4v (F . tularensis SchuS4 gray variant).
Table 1 | Trimethylsilyl methyl glycoside analysis of OSs purified from 
the LPS of Ft LVS LPS and the gray variant Ft LVSg LPS.
OS  Man  gal  glc  QuiNAc*  galNAc  Kdo
LVS  13  18  28  36  3  3
LVSG  24  5  62  0.5  7  3
*The amount of the QuiNAc could not be precisely quantified since there is no 
original standard available and, therefore, quantification was based on using the 
response factor for GlcNAc.
Man, mannose; Gal, galactose; Glc, glucose; QuiNAc, 2-acetamino-2,6,dideoxy-
d-glucose; GalNAc, N-acetyl galactosamine; Kdo, 3-deoxy-d-manno-octulosonic 
acid.
and anti-F. novicida LPS monoclonal antibodies (Figure 2D). The 
results showed that Ft LVS LPS reacted with both the F. tularensis 
monoclonal and FB-11 antibodies showing the typical LPS   laddering, www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  7
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We also see resonances that are consistent with the published core 
structure with the exception that we do not observe evidence for 
the core GalNAc residue. The Ft LVS and Ft LVSG proton spectra 
clearly differ from one another indicating that the Ft LVSG Fraction 
3 contains different structures than found in the Ft LVS Fraction 3. 
Therefore, since the OSs in Fraction 3 would be those that would 
comprise the core region, as well as some possible truncated OPS, 
these data support the conclusion that the Ft LVSG has an altered 
core region compared to that of Ft LVS.
analysIs of FT lvsG lIpId a demonstrates a reductIon In 
GalactosamIne modIfIcatIon
Cowley et al. (1996) demonstrated that Ft LVSG lipid A versus that 
of Ft LVS elicited increased NO induction in rat macrophages. 
We confirmed this finding (NO production by rat macrophages 
measured as nitrate by the Griess reagent system) by both Ft LVSG 
LPS and purified lipid A (data not shown). This suggested that the 
lipid A of Ft LVSG was different than that of Ft LVS. To explore 
these differences, we performed structural analyses on purified lipid 
A of Ft LVS and Ft LVSG. MALDI-TOF analysis in negative and 
positive ion mode was performed on replicate lipid A   preparations. 
These LPS samples were reacted in a Western blot with anti-F. 
tularensis or anti-F. novicida polyclonal sera generated from infected 
mice (Figure 2E). Ft LVS LPS and F. novicida LPS only reacted 
with their respective antisera while Ft LVSG now reacted only with 
F. tularensis polyclonal sera. These results suggest that changes in 
the Ft LVSG LPS are specifically recognized by monoclonal but not 
polyclonal antibodies.
We next isolated and performed extensive NMR analyses on 
the Ft LVS and Ft LVSG OPSs to determine if any structural dif-
ferences could be detected between these molecules. Crude LPS 
was enzymatically treated to remove contaminating nucleic acids 
and proteins and ultracentrifuged. The LPS pellet was collected 
and the carbohydrate portion of LPS was released from lipid A 
via mild hydrolysis. The carbohydrate fractions from Ft LVS and 
Ft LVSG of were resolved by HPLC. The carbohydrates eluted in 
three primary fractions. Fraction 1 contained the OPS, Fraction 
2 contained slightly lower molecular weight OPS, and Fraction 3 
contained the core OSs with some possibly low molecular weight 
OPS repeat units. From these results, the Fraction 1/3 ratio for Ft 
LVS LPS is 17, while it is 4.6 for LVSG (Table 2). These results are 
consistent with the above data showing that the Ft LVSG strain 
contains less OPS as reflected by the lower QuiN level during 
composition analysis. Fractions 1 and 3 were analyzed by NMR 
spectrometry. Fraction 1 from both Ft LVS and Ft LVSG were com-
pared to each other using 2D NMR experiments – COSY, TOCSY, 
NOESY, and HSQC (data not shown). These results indicate that 
the OPS from Ft LVS and Ft LVSG have the same structures. In 
addition, the data are completely consistent with the structure 
reported for F. tularensis strain 15, strain SchuS4, and OSU10 
(Vinogradov et al., 2002; Prior et al., 2003; Thirumalapura et al., 
2005). The results clearly support the conclusion that Ft LVS and 
Ft LVSG have the following OPS structure as previously reported 
for the above F. tularensis strains:
-4)-α-D-GalpNAcAN-(1 → 4)-α-D-GalpNAcAN-(1 → 3)-β-D-
QuipNAc-(1 → 2)-β-D-Quip4Fo-(1 → 
The differential staining with the F. tularensis and F. novicida 
monoclonal antibodies coupled with the fact that the F. novicida 
monoclonal antibody binds to the LMW LPS and is, therefore, 
likely binding to the core OS, suggests that the true monoclonal 
antibody-tracked alteration between Ft LVS and Ft LVSG is related 
to the core region. Therefore, we analyzed OSs found in Fraction 
3 from Ft LVS and Ft LVSG by 1D proton NMR spectroscopy. The 
results are shown in Figure 3. The spectrum of Ft LVS Fraction 
3 indicates that a small amount of truncated OPS is still present. 
Table 2 | Main fraction and yields obtained in gel filtration using 
Superdex peptide column.
Oligosaccharide  HPLC Fr1 (mg)  HPLC Fr2 (mg)  HPLC Fr3 (mg) 
  (tube 18–25)  (tube 26–28)  (tube 29–50)
Ft LVS  7.62*  0.3  0.46**
Ft LVSG  0.65*  0.02  0.14**
*Used in 1D and 2D NMR experiments.
**Used in 1D NMR experiments.
Figure 3 | The proton NMr spectra of the LPS core region 
oligosaccharides from Ft LVS and Ft LVSg. The proton NMR spectra of the 
oligosaccharides found in Fraction 3 from Ft LVS (top) and Fraction 3 from Ft 
LVSG (bottom) are shown. The resonances marked with # are likely due to 
OPS fragments. Those marked with * are due to contaminating acetate and 
lactate. Thus, non-marked resonances denote the LPS core region.Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 129  |  8
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of the flmF2 gene in Ft LVS, which eliminates the galactosamine 
modification, reduced the frequency of phase variation from 30% to 
5-7% in stationary phase liquid cultures. Though F. novicida strains 
carrying this mutation have been shown to affect mouse virulence 
and cytokine/chemokine induction in macrophages, the Ft  LVS 
flmF2 mutant demonstrated no defect in survival in macrophages 
of mouse (Raw, J774.1 and MH-S), rat (bone marrow derived, 
alveolar), or human (THP-1 and monocyte derived macrophages) 
origin (data not shown, see below section).
the FT lvsG varIant has a rat and human But not mouse 
IntramacrophaGe survIval defect
It has been shown previously by Cowley et al. (1996) that Ft LVS 
and Ft LVSG intracellular growth/survival was similar in mouse 
macrophages, but that differences in growth/survival could be visu-
alized in rat bone marrow-derived macrophages. We examined the 
survival of Ft LVS and Ft LSVG in various macrophages including 
J774.1 (a mouse macrophage cell line), MH-S (a mouse alveolar 
macrophage cell line) and mouse bone marrow-derived macro-
phages and did not find any significant differences in survival of Ft 
LVS and Ft LSVG (data not shown). However, we observed that Ft 
LVSG survived less well in rat bone marrow derived macrophages 
and a rat alveolar macrophage cell line (ATCC# CRL-2192) and 
that this inhibition of growth of Ft LVSG can be reversed by using 
the NO inhibitor NMMA (data not shown). These findings were 
consistent with the previous findings of Cowley et al. (1996). We 
Both showed the absence of a peak at m/z 1666 in Ft LVSG that 
was present in Ft LVS. It is known that this peak represents the 
addition of galactosamine (161 Da) to the basic structure at m/z 
1504 (2× GlcN, 3× C18:0 (3-OH), C16:0, P), though previous data 
suggested that this modification was not observed in the Ft LVS 
strain (Kanistanon et al., 2008; Figures 4A,B). This was the only 
structural alteration noted. Since the MALDI-TOF analysis is only 
semi-quantitative, we performed galactosamine quantitation assays 
to further demonstrate the reduced galactosamine modification 
of lipid A in Ft LVSG. The lipid A was derivatized and analyzed 
by GC–MS. F. novicida showed the highest degree of modification 
at 25% while Ft LVS was at 14%. Both Ft LVSG and Ft LVSGD 
showed  reduced  galactosamine  modification,  with  6  and  7%, 
respectively (Figure 5A).
Three genes have been identified that are responsible for galac-
tosamine or mannose lipid A modification (Gunn and Ernst, 2007; 
Kanistanon et al., 2008). The transferases FlmF1 and FlmF2 are 
required for adding mannose or glucosamine residues, respectively, 
to the lipid A. The glycosyltransferase FlmK can add both mannose 
and galactosamine to lipid A (Gunn and Ernst, 2007; Kanistanon 
et al., 2008). A real-time PCR assay was performed on the genes 
flmF2 and flmK from Ft LVS and Ft LVSG to determine if their 
expression was altered and might be responsible for the observed 
lipid A galactosamine modification alteration. Expression of both 
genes was found to be significantly less in Ft LVSG (Figure 5B), cor-
relating with the reduction in galactosamine modification. Mutation 
Figure 4 | Structural analysis of lipid A. (A) MALDI-TOF analysis of lipid A of Ft LVS and Ft LVSG. The boxed m/z denotes the species containing galactosamine 
that shows differential relative intensity between Ft LVS and Ft LVSG. (B) The m/z 1666 structure of lipid A of Ft LVS.www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  9
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then examined intramacrophage survival in human MDMs and 
the THP-1 macrophage-like cell line. We observed that the Ft LVSG 
strain survived less well over the first 12 h post-infection in both 
cell types with macrophage cell death at later time points. The 
defect was most prominent for the MDMs, where the Ft LVSG 
strain demonstrated nearly a log defect in survival at 12 h post-
infection versus the Ft LVS strain (Figure 6). Thus, the Ft LVSG 
strain has an intramacrophage survival defect in rat and human 
but not mouse macrophages.
FT lvsG and FT lvs are sImIlarly vIrulent In the mouse model 
But dIfferentIally protect aGaInst F. TuLArenSIS schus4 
challenGe
Gray variants have been shown to be less virulent (Eigelsbach and 
Downs, 1961) and/or less protective as vaccines against F. tularen-
sis SchuS4 challenge (Eigelsbach and Downs, 1961; Cowley et al., 
1996; Hartley et al., 2006; Conlan and Oyston, 2007) However, 
the specific virulence of the Ft LVSG strain in the mouse model 
of tularemia has not been determined. To compare the virulence 
of Ft LVS and Ft LVSG, BALB/c mice were infected with 100 CFU 
of Ft LVS and Ft LVSG intranasally and observed for survival. 
Both Ft LVS and Ft LVSG infected mice demonstrated 80% sur-
vival (N = 10 mice; Figure 7A). The surviving mice were chal-
lenged with 1000 CFU of F. tularensis SchuS4 (∼100-fold above 
the LD50) intranasally 4 weeks post vaccination (Figure 7B). All 
Ft LVS vaccinated mice (N = 8) survived the challenge whereas 
Ft LVSG vaccinated mice (N = 8) could not survive the challenge 
and succumbed to infection within 5 days. These results suggest 
that Ft LVSG is as virulent in mice as Ft LVS but it does not protect 
against Type A challenge.
Figure 5 | (A) Glucosamine quantification in the lipid A samples. (B) 
Differential expression of LPS modification genes flmF2 and flmK in Ft LVS 
and Ft LVSG as determined by real-time PCR. RCN-Relative copy number, 
actual values are shown above the bars.
Figure 6 | intramacrophage survival assay of Ft LVS and Ft LVSg in 
human monocyte-derived macrophages. Symbols: diamond, Ft LVS; 
square, Ft LVSG. The data presented is from an assay performed in triplicate 
with little variation between replicates (resulting in non-visible error bars), and 
this experiment was performed three times on separate occasions with 
similar results.
Figure 7 | Virulence assays in the mouse model of tularemia. (A) The 
virulence of Ft LVS and Ft LVSG in mice inoculated by the intranasal route. 
Symbols: diamond, Ft LVS; square, Ft LVSG. N = 10 mice per strain. (B) 
Challenge of vaccinated mice with F . tularensis SchuS4. Symbols: diamond, Ft 
LVS; square, Ft LVSG. N = 8 mice per strain.
dIscussIon
Francisella tularensis LVS has been known to phase vary from a 
blue (i.e., wildtype) to a gray variant since the phenomenon was 
first described by Eigelsbach in 1951 (Eigelsbach et al., 1951). 
Such variation has proven to be an issue historically in vaccine 
production runs of Ft LVS (Conlan and Oyston, 2007; Oyston, Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 129  |  10
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distinct core OSs (an F. novicida monoclonal antibody reactive and 
an Ft monoclonal antibody reactive), but cannot add O-antigen to 
the “F. novicida-like” core. Ft LVSG, on the other hand, can either 
produce both core types and ligate O-antigen to both, or can only 
make the F. novicida reactive core type and can add O-antigen 
to this core.
Regarding the mechanism of O-antigen chain length reduction/
differential O-antigen ligation, these processes are typically medi-
ated by an O-antigen ligase (e.g., RfaL), O-antigen polymerase (e.g., 
Wzy) and a chain length determinant (e.g., Cld). Francisella spp. 
appear to have multiple proteins with homology to RfaL, and their 
differential expression may account for the observed O-antigen 
phenotypes. BLAST searches of the Ft LVS genome with the RfaL 
locus of Salmonella typhimurium revealed three high scoring loci: 
FTL1122 (41% identity but 188 amino acids in Ft LVS versus 292 
amino acids in F. tularensis SchuS4), FTL 0706 (37% identity), and 
FTL0598 (26% identity, called the wzy locus in Ft LVS; Prior et al., 
2003). Surprisingly, BLAST searches with the S. typhimurium Wzy 
showed no strong identity to Francisella proteins. No Cld ortholog 
exists in F. tularensis (Prior et al., 2003; our recent BLAST searches). 
It is unclear if another unknown enzyme serves this function or 
is the O-antigen chain length is unregulated in this bacterium. 
Thus, it is possible that multiple or novel proteins mediate the 
O-antigen polymerase, ligase and length determination functions 
in Francisella and may be responsible for the core/O-antigen data 
described here. Further biochemical analysis is ongoing to deter-
mine the exact structural changes in the Ft LVSG LPS core region, 
as are genetic experiments to identify genes conferring F. novicida 
monoclonal antibody reactivity to Ft LVS.
The lipid A regions of Ft LVS and Ft LVSG were shown to 
be identical with the exception of a galactosamine modification, 
which was reduced/absent in the Ft LVSG variant. The galactos-
amine modification was not detected previously in Ft LVS, but 
was clearly evident in the Ft LVS strain analyzed here. Mannose is 
also observed as a modification of lipid A in F. novicida and Type 
A subspecies, but not Type B subspecies (the background of the 
Ft LVS strain). Consistent with these published data, mannose was 
not observed in our assays. While the flmF2 (glucosamine addi-
tion) and flmK (both mannose and glucosamine addition) genes 
showed reduced transcription in the Ft LVSG strain consistent 
with the reduced lipid A modification, mutants in these genes in 
Ft LVS did not result in the small colony or gray phenotype on 
plates nor were the mutants defective in intramacrophage survival. 
Thus, these mutants did not exhibit obvious characteristics of the 
Ft LVSG gray variant. These mutants did, however, demonstrate 
a dramatically reduced phase variation rate to gray variants, sug-
gesting that galactosamine modification may be involved in but is 
not sufficient for the gray phenotype. Further phenotypic testing 
(e.g., lipid A NO induction, mouse virulence) is ongoing, as is the 
construction of a double flmF2 flmK mutant. It is also possible that 
no expression versus reduced expression of these enzymes may 
have different effects, but titrated gene expression in Francisella 
is not yet a reality, so this concern will be addressed when the 
technology is available.
Experiments performed in this study confirmed those of Cowley 
et al. (1996) regarding increased NO induction in rat but not mouse 
phagocytes by the gray strain LPS. This correlated with decreased 
2009). The Ft LVS gray variants are problematic because they are 
dramatically less efficacious than the blue colony morphotypes in 
protection studies against the virulent F. tularensis Type A strain. 
The phenotypes associated with the gray variants are quite vari-
able, as they have been described to give rise to different colony 
sizes and opacity, but the only two that have been molecularly 
characterized share the characteristic of LPS alteration. While this 
characteristic is shared, this also presents yet another difference, 
as the gray variant described by Hartley et al. (2006), (similar to 
Ft LVSGD studied in this work) has been shown to lack O-antigen 
while Ft LVSG still possessed an O-antigen, albeit reduced in 
amount, which has altered F. novicida/F. tularensis-LPS specific 
monoclonal  antibody  reactivity  patterns.  Thus,  gray  variants 
are themselves variable, but an increased understanding of the 
mechanism(s) behind this variation would aid future tularemia 
vaccine production.
In addition to the presence/absence of the O-antigen, we dem-
onstrate biochemically that the Ft LVSG O-antigen chain carbo-
hydrates are reduced in Ft LVSG versus Ft LVS. It is unclear if this 
demonstrates that the O-antigen chain length of LVSG is shorter 
or if the lipid A plus core is capped less efficiently with O-antigen. 
A reduction in Ft LVSG O-antigen chain carbohydrates was pre-
viously suggested in a manuscript by Clay et al. (2008) based on 
evidence from silver staining patterns and Western blot analysis. 
Clay et al. (2008) also demonstrated that the Ft LVSG strain was 
bound by complement component C3 in higher amounts than 
Ft LVS and was dramatically more susceptible to complement-
mediated killing. It is of interest that, while susceptible to comple-
ment, Ft LVSG is still as virulent as Ft LVS in the mouse model. It 
is likely that the effect of complement-mediated killing is quantita-
tive rather than absolute and that the current mouse model is not 
sensitive enough to record an effect. Alternatively, the result in the 
mouse model may reflect a fundamental difference in complement 
function between mouse and man. For example, it is known that 
C3 in mouse serum is more labile than in human serum and this 
may result in different levels of C3 opsonization and regulation in 
mouse versus human serum.
Both F. tularensis and F. novicida anti-LPS monoclonal antibod-
ies reacted with LVSG, which had been interpreted to demonstrate 
that the O-antigen of Ft LVSG was altered, creating an epitope(s) 
reactive to both antibodies. However, closer examination of the 
Western blots show F. novicida monoclonal antibody reactivity to 
Ft LVSG LPS with low molecular weight species, likely lipid A plus 
core, as well as higher species containing lipid A, plus core, plus 
O-antigen repeats. The F. novicida anti-LPS monoclonal antibody 
reacted only with the low molecular weight species to Ft LVS LPS. 
This suggested that the F. novicida anti-LPS monoclonal antibody 
recognized a core epitope and that core, and not the O-antigen 
regions of Ft LVS and Ft LVSG, may differ. This was confirmed by 
NMR analysis of purified LPS carbohydrates, which demonstrated 
identity between the Ft LVSG and Ft LVS O-antigen regions while 
the LPS core region of Ft LVSG was different from that of Ft LVS. 
If, as we suspect, the F. novicida anti-LPS monoclonal antibody 
epitope is within the core region and the Ft LVS anti-LPS mono-
clonal epitope is within the O-antigen, then because of observed 
Western blot reactivities, both Ft LVS and Ft LVSG contain an 
“F. novicida-like” core. Thus, it is possible that Ft LVS makes two www.frontiersin.org  November 2010  | Volume 1  | Article 129  |  11
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survival of these gray variants in rat and human macrophages, 
which could be reversed in rat macrophages by the addition of a 
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strain intracellular survival with the inherent capabilities of the 
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ing the involvement of additional factors.
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